Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Decrease in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 33,421 shares, a drop of 58.4% from the May 14th total of 80,248 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 57,636 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on NBTX shares. UBS Group increased their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Guggenheim increased their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Leerink Partners increased their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and an average price target of $37.33.

Nanobiotix Stock Performance

Shares of NBTX opened at $35.33 on Friday. The company’s 50 day simple moving average is $37.60 and its 200-day simple moving average is $29.36. Nanobiotix has a 12-month low of $4.18 and a 12-month high of $57.14.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million for the quarter. As a group, analysts expect that Nanobiotix will post 0.19 earnings per share for the current year.

Hedge Funds Weigh In On Nanobiotix

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new position in Nanobiotix in the 4th quarter valued at $390,000. Marshall Wace LLP purchased a new position in Nanobiotix in the 4th quarter valued at $220,000. Optiver Holding B.V. acquired a new stake in Nanobiotix in the third quarter valued at $101,000. Finally, Royal Bank of Canada lifted its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.